Evidence map›Paper›PMID 39090078›Full record

ArticleThe pharmacogenomics journal2024

Opioid use disorder risk alleles in self-reported assigned African American/Afro-Caribbean and European biogeographical genetic ancestry groups and in males and females.

Jon E Sprague, Caroline E Freiermuth, Joshua Lambert, Robert Braun, Jennifer A Frey, Daniel J Bachmann, Jason J Bischof, Lauren Beaumont, Michael S Lyons, Michael V Pantalon and 3 more

Abstract read
In one paragraph

Article in The pharmacogenomics journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Associations ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jon E SpragueBowling Green State University, The Ohio Attorney General's Center for the Future of Forensic Science, Bowling Green, OH, USA. jesprag@bgsu.edu.ORCID 0000-0003-0349-5072
Caroline E FreiermuthDepartment of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA.
Joshua LambertCollege of Nursing, University of Cincinnati, Cincinnati, OH, USA.
Robert BraunDepartment of Emergency Medicine, University of Cincinnati, Cincinnati, OH, USA.
Jennifer A FreyDepartment of Emergency Medicine, The Ohio State University, Columbus, OH, USA.
Daniel J BachmannDepartment of Emergency Medicine, The Ohio State University, Columbus, OH, USA.
Jason J BischofDepartment of Emergency Medicine, The Ohio State University, Columbus, OH, USA.ORCID 0000-0001-5950-130X
Lauren BeaumontDepartment of Pharmaceutical Sciences and Pharmacogenomics, College of Pharmacy, Natural and Health Sciences, Manchester University, Fort Wayne, IN, USA.
Michael S LyonsDepartment of Emergency Medicine, The Ohio State University, Columbus, OH, USA.
Michael V PantalonDepartment of Emergency Medicine, Yale University School of Medicine, New Haven, CT, USA.
Brittany E PunchesDepartment of Emergency Medicine, The Ohio State University, Columbus, OH, USA.
Rachel AnconaWashington University School of Medicine, St. Louis, MO, USA.
David F KisorDepartment of Pharmaceutical Sciences and Pharmacogenomics, College of Pharmacy, Natural and Health Sciences, Manchester University, Fort Wayne, IN, USA.ORCID 0000-0001-7215-7734

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The influence of genetic variants related to opioid use disorder (OUD) was evaluated using multiple logistic regression analysis in self-reported assigned African American/Afro-Caribbean and European biogeographical ancestry groups (BGAGs) and by sex. From a sample size of 1301 adult patients (>18 years of age) seen in emergency departments of three medical centers in Ohio, six variants were found to be associated with OUD. Two of the variants, rs2740574 (CYP3A4) and rs324029 (DRD3), were included in the analysis having met criteria of at least five subjects for each BGAG, variant carrier status, and OUD status combinations. Variant carriers in the African/Afro-Caribbean BGAG had slightly lower predicted probabilities of OUD. Variant carriers in the European BGAG had slightly higher predicted probabilities of OUD. Relative to sex, all the six variants met evaluation criteria (five subjects for all sex, variant, and OUD status combinations). No statistically significant interactions were found between a given variant, BGAGs and sex. Findings suggest variant testing relative to OUD risk can be applied across BGAGs and sex, however, studies in larger populations are needed.

Indexed as

AllelesBlack or African AmericanOpioid-Related DisordersWhite PeopleAdultBlack PeopleCaribbean PeopleCytochrome P-450 CYP3AFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedPolymorphism, Single NucleotideRisk FactorsSelf ReportCYP3A4 protein, humanCytochrome P-450 CYP3A

Identifiers

PMID39090078
PMCPMC11294185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.